Immune checkpoint inhibitors versus ramucirumab plus docetaxel for refractory or relapsed advanced non-small cell lung cancer: A systematic review and network meta-analysis of phase 3 randomized clinical trials.
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000041086
- Lead Sponsor
- Showa University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1526
Inclusion Criteria
Not provided
Exclusion Criteria
(The article search were restricted to those published in the English language)
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method